Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(CSE: MDMA )

0.2800 -0.0150 (-5.08%)
Official Closing Price Updated: 3:59 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about MDMA

PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA
From PharmAla Biotech
Via GlobeNewswire
PharmAla Launches MDMA Clinical Trial Tool for Researchers
From PharmAla Biotech
Via GlobeNewswire
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
From PharmAla Biotech
Via GlobeNewswire
Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilities 
From PharmAla Biotech
Via GlobeNewswire
Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilities 
From PharmAla Biotech
Via GlobeNewswire
Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
Novel MDMA-Like Drug Could Be Used for Numerous Neurological and Psychiatric Indications 
From PharmAla Biotech
Via GlobeNewswire
Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
PharmAla now first company to supply both MDMA and Psilocybin into the Australian Market 
From PharmAla Biotech
Via GlobeNewswire
PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing
New ticker symbol goes into effect immediately 
From PharmAla Biotech
Via GlobeNewswire
PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance
PharmAla to present its intellectual property assets to potential partners at the annual JPM healthcare conference on January 8-11th in San Francisco 
From PharmAla Biotech
Via GlobeNewswire
PharmAla Begins Trading on OTCQB
From PharmAla Biotech
Via GlobeNewswire
PharmAla Files Patent for Novel MDXX Molecule PharmAla-1
Patent Filing Follows Year of Preclinical Research, Academic Publication 
From PharmAla Biotech
Via GlobeNewswire
Life Science Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Life Science Investor Forum Agenda Announced for June 22nd
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
USFDA Approves LaNeo MDMA for Clinical Trial Use in the United States
From PharmAla Biotech
Via GlobeNewswire
PharmAla Biotech to form Australian Psychedelics Joint Venture with Vitura Health
From PharmAla Biotech
Via GlobeNewswire
Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development
From Revive Therapeutics Ltd.
Via GlobeNewswire
Australia Allows Prescription of MDMA and Psilocybin in Groundbreaking Regulatory Change
PharmAla Biotech is the only company in the world with the ability to ship GMP MDMA and Psilocybin today 
From PharmAla Biotech
Via GlobeNewswire
The Power Play by The Market Herald Releases New Interviews with Pharmala Biotech Holdings, Nextech AR Solutions and Enertopia Discussing Their Latest News
Via ACCESSWIRE
KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
PharmAla Completes Pre-IND Meeting with FDA, to Present at KCSA Virtual Investor Conference
Company invites individual and institutional investors, as well as advisors and analysts, to attend its real-time, interactive presentation 
From Virtual Investor Conferences
Via GlobeNewswire
KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement
PharmAla will be the exclusive global reseller of Mindset’s cGMP psilocybin to appropriately licensed clinical researchers 
From PharmAla Biotech
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.